DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening for Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds that have been approved by major agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or are listed in pharmacopeias [Product Page]. Each compound is pre-dissolved at 10 mM in DMSO, supporting robust high-throughput and high-content screening workflows. The library is designed for drug repositioning and pharmacological target identification, leveraging well-characterized mechanisms of action including enzyme inhibition, receptor modulation, and channel regulation. Recent peer-reviewed studies have validated the utility of FDA-approved libraries for identifying synergistic drug interactions and novel inhibitors, such as metallo-β-lactamase inhibitors rescuing carbapenem efficacy (Guo et al., 2024, DOI). Stability and format flexibility (96-well, deep well, 2D barcoded tubes) enable reliable integration into diverse research pipelines.

Biological Rationale

Drug libraries containing FDA-approved compounds offer high translational potential due to established human safety profiles and well-defined pharmacology. The rapid deployment of such libraries in screening workflows enables identification of new indications (drug repositioning) and facilitates mechanism-based studies. The DiscoveryProbe™ FDA-approved Drug Library provides a broad spectrum of molecular targets, representing diverse classes such as kinase inhibitors (e.g., imatinib), metabolic modulators (e.g., metformin), and chemotherapeutics (e.g., doxorubicin). This diversity supports investigation of signal pathway modulation, enzyme inhibitor screening, and disease model validation. The use of FDA-approved entities allows for faster transition from in vitro findings to preclinical and clinical applications, reducing the attrition rate typical of early drug discovery pipelines [Contrast: Reference Standard for Translational Research].

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library encompasses compounds with well-characterized and diverse mechanisms of action:

• Receptor agonists and antagonists: Target G-protein coupled receptors, nuclear hormone receptors, and ion channels.
• Enzyme inhibitors: Inhibit kinases, proteases, and metabolic enzymes, such as mTOR, topoisomerase, and β-lactamases.
• Ion channel modulators: Affect ion flux and membrane potential, impacting neural activity and cardiac function.
• Signal pathway regulators: Modulate pathways like PI3K/AKT/mTOR, MAPK, and NF-κB for detailed mechanistic studies.

This mechanistic diversity is essential for broad-based pharmacological screens, target deconvolution, and validation in disease-relevant models. For example, the library enabled identification of metallo-β-lactamase inhibitors that restore carbapenem efficacy against drug-resistant bacteria, as demonstrated by nitrocefin hydrolysis and checkerboard MIC assays (Guo et al., 2024).

Evidence & Benchmarks

• Screening the DiscoveryProbe™ FDA-approved Drug Library led to identification of twelve compounds inhibiting NDM-1 metallo-β-lactamase activity, with four (dexrazoxane, embelin, candesartan cilexetil, nordihydroguaiaretic acid) showing broad-spectrum inhibition and in vitro synergy with meropenem (Guo et al., 2024).
• High-throughput and high-content screening using pre-dissolved 10 mM DMSO solutions in 96-well and deep-well plates enabled rapid, reproducible assessment of pharmacological effects across cancer and neurodegenerative disease models (TCS359 summary).
• Stability studies confirm compound integrity for 12 months at -20°C and 24 months at -80°C (Product Page).
• In vivo efficacy of repositioned drugs from the library was validated in three mouse infection models, demonstrating significant bacterial clearance and restoration of carbapenem sensitivity (Guo et al., 2024).
• Mechanism-driven compound libraries, such as DiscoveryProbe™, accelerate translational research by bridging mechanistic insight and clinical innovation in complex diseases (Mechanism to Medicine).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a wide array of research and translational applications:

• Drug repositioning screening: Rapid identification of new indications for approved drugs, as exemplified by β-lactamase inhibitor discovery (Guo et al., 2024).
• Pharmacological target identification: Elucidation of molecular targets and pathway modulators in disease models (Contrast: Emphasis on Oncology & Neurodegeneration).
• Cancer and neurodegenerative disease drug discovery: Screening for cytotoxicity, proliferation inhibition, and neuroprotection using established clinical drugs.
• Enzyme inhibitor screening: Identification of compounds modulating key enzymes (e.g., kinases, β-lactamases, proteases).
• Signal pathway regulation studies: Investigation of pathway-specific effects using annotated compounds.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for every assay format: Some compounds may interfere with fluorescence or luminescence readouts due to intrinsic properties.
• Drug concentrations in library (10 mM in DMSO) may require further dilution: Direct application without optimization can lead to off-target effects or DMSO toxicity.
• Library is not a comprehensive representation of all druggable chemical space: It contains only approved (or pharmacopeia-listed) compounds, excluding investigational or novel chemotypes.
• Screening outcomes may not predict in vivo efficacy: Positive in vitro results require subsequent pharmacokinetic and safety validation.
• Not designed for de novo drug discovery: The library is optimized for repositioning and mechanistic studies, not for identification of entirely new chemical entities.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in multiple user-friendly formats, including:

• 96-well and 384-well microplates for HTS and HCS platforms.
• Deep well plates and 2D barcoded screw-top tubes for flexible sample tracking and storage.
• Compounds pre-dissolved at 10 mM in DMSO, aliquoted under inert atmosphere to prevent oxidation.
• Shipping on blue ice (evaluation samples) or room temperature/blue ice (bulk formats) ensures stability and traceability.

Standard workflow integration involves plate thawing, dilution to assay-appropriate concentrations (typically 0.1–10 μM), and direct application to cell-based or biochemical assays. Compound integrity is maintained for 12 months at -20°C or 24 months at -80°C. Researchers are advised to validate DMSO tolerance for their specific assay platforms. For detailed protocol recommendations, see this workflow article, which this review extends by providing updated peer-reviewed evidence on in vivo efficacy and mechanistic insights.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated and versatile resource for high-throughput and high-content screening in drug repositioning, mechanistic biology, and pharmacological target identification. Peer-reviewed studies confirm its ability to enable rapid discovery of clinically actionable compounds, such as metallo-β-lactamase inhibitors restoring carbapenem efficacy. Its stability, mechanistic diversity, and proven integration into translational pipelines make it a reference standard for modern biomedical research. Future developments may include expansion with newly approved drugs and integration with AI-driven screening platforms to further accelerate therapeutic innovation. For product specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library page.